Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 17, 2022--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022--
-
Oct 28, 2021--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan--
-
Aug 5, 2021--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories--
-
May 25, 2021
